Amgen Tops Sales and Profit Estimates, Boosts 2016 Forecast

  • Sales of top drugs Enbrel, Neulasta, Aranesp all increase
  • Revenue rises 9.8%, profit jumps 17%, aided by cost-cutting

Amgen Inc., boosted by higher drug sales and the effects of a cost-cutting campaign, reported first-quarter revenue and profit that topped analysts’ estimates. The biotechnology giant raised its forecast for the year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.